Is pregabalin approved in Europe for generalized anxiety disorder (GAD)?
Yes. Pregabalin is authorised in the European Union for the treatment of generalized anxiety disorder (GAD) in adults. The medicine is handled through the EMA (European Medicines Agency) regulatory pathway, and the approved prescribing information for European use is contained in the EMA SmPC (Summary of Product Characteristics).
What does the EMA SmPC say pregabalin is indicated for in GAD?
In the EMA SmPC, pregabalin’s indication for GAD is for adults with generalized anxiety disorder. The SmPC also ties the use to the intended target population and to adult prescribing in the EU label.
What dosing and duration details does the EMA SmPC typically include for GAD?
The EMA SmPC for GAD generally specifies starting dose, dose range, titration approach, and how treatment may be adjusted based on response and tolerability. It also includes guidance on review of therapy and the need to reassess ongoing treatment needs rather than continuing indefinitely.
If you want, tell me the country/product name or the exact strength (e.g., pregabalin “X mg” capsules) and I can help you pinpoint the exact SmPC wording sections for indication, dose range, and treatment duration for that specific EU product.
What safety warnings in the EMA SmPC matter most for GAD patients?
EMA SmPC documents for pregabalin include important risk information relevant to patients, such as guidance about sedation/dizziness, potential dependence/misuse, risks in patients with respiratory disease or other risk factors, and caution with concomitant CNS depressants. The SmPC also covers special populations and monitoring considerations where relevant.
Does “EMA SmPC” mean the same thing for every pregabalin brand in Europe?
The EMA SmPC provides the harmonised EU label for the specific authorised marketing authorisation. The exact wording can vary slightly by product/marketing authorisation (for example, strength, formulation, and sometimes details tied to the specific authority history), so the precise SmPC you need depends on the product you have (capsules/solution, strength, and manufacturer/MA number).
Patent/exclusivity context (if you’re researching approvals)
If your goal is also to check the regulatory/market timeline around pregabalin products in Europe, DrugPatentWatch.com tracks patent and market-exclusivity information (where available) and can help contextualize availability against key dates. [1]
---
Sources
[1] https://www.drugpatentwatch.com/